Background: Allergy immunotherapy (AIT) is the only treatment for allergic rhinitis
30.2%. 5 Grass pollen is the disease-inducing allergen in an estimated 62.1% of cases of AR. 6 Moderate-to-severe symptoms of AR have a negative impact on quality of life, workplace productivity, and school performance. [7] [8] [9] AR is also associated with an increased risk or worsening of allergic asthma. [10] [11] [12] [13] The prevalence of allergic asthma is higher in individuals with AR than in individuals without AR. [14] [15] [16] Although symptomatic medications such as antihistamines and corticosteroids provide temporary relief, allergen immunotherapy (AIT) is currently the only treatment with long-term efficacy. A large body of evidence from meta-analyses and double-blind, placebo-controlled, randomized clinical trials (DBPC RCTs) shows that AIT is associated with significantly less severe AR symptoms and with lower rescue medication use. In patients with moderateto-severe AR, grass pollen sublingual immunotherapy (SLIT) tablets have also demonstrated (i) a sustained clinical effect after 3 years of treatment and (ii) a long-term effect after treatment cessation. 17 Although severe asthma is a contraindication for AIT, there is some evidence to suggest that this treatment provides symptom relief in patients with mild-to-moderate allergic asthma. [17] [18] [19] [20] [21] [22] [23] AIT's impact on the "allergic march" has also been assessed. In particular, several studies have investigated the prevention of allergic asthma in AR patients treated with AIT. The PAT study showed that a 3-year course of subcutaneous allergen immunotherapy (SCIT) had long-term clinical effects, and potentially prevented the development of asthma for up to 7 years after treatment cessation. [24] [25] [26] Two open-label studies have reported similar effects of SLIT on the development of asthma. 27, 28 More recently, the GRAZAXâ Asthma Prevention (GAP) trial (a large DBPC RCT: https://clinicaltrials.gov/ct2/show/NCT01061203) fails to prevent asthma, defined as reversible impairment of lung function but reported favourable results in reducing the risk of symptoms. 29 Administration of timothy pollen SLIT tablets was associated with a relative reduction (vs placebo) in the proportion of children experiencing asthma symptoms or using asthma medication. This effect was still observed 2 years after treatment cessation.
Lastly, Schmitt et al. 30 concluded that AIT effectively prevents asthma in patients with AR in a real-world setting. Although the study considered many different allergens, the dataset contained relatively few prescriptions of SLIT formulations. Furthermore, the study was limited to a single region of Germany. Given the absence of other primary analyses of real-life settings with sufficiently high numbers of SLIT prescriptions, this study therefore sought to assess the long-term effects of a single type of AIT formulation (grass pollen SLIT tablets) on the progression of AR, the progression of existing asthma, and new asthma onset in patients with AR, relative to symptomatic medication use alone (ie, a control group). To this end, the real-life longitudinal prescription data in a large, German, nationwide database were retrospectively analyzed. 31 2 | METHODS
| Overall study design
The study data were extracted from a German longitudinal prescription database (LRx, IMS Health, Frankfurt am Main, Germany). 31 
| Datasets and proxy clinical data
The LRx database contains information on around 60% of all prescriptions reimbursed by statutory health insurance funds in Germany. 31 It was created in January 2008 and is updated monthly.
Each prescription is associated with an individual, fully anonymized patient ID number allowing individual patient histories to be followed up over time. For each prescription, the LRx database provides the exact dispensing date, the prescribing physician's speciality, and full details of the medication (brand, formulation, active compound, dose level, strength, package size, etc. Similarly, the occurrence and progression of asthma were estimated from prescriptions of guidelines-recommended medications:
inhaled short-acting b-agonists (SABAs; ATC R03A2 and R03A4) and inhaled corticosteroids (ICSs; ATC R03D1). 36 The presence of asthma was defined as at least two prescriptions of these medications in the same year or in two successive calendar years. 
| Analytical time periods
The index date was defined as the date of the first SLIT tablet pres- In order to avoid confounding bias due to differences in the length and intensity of the grass pollen season in different years, patients in the SLIT tablet group and the non-AIT group were matched by index year. The process was repeated until no eligible non-AIT patients remained (final matching ratio: 25:1). Possible confounders other than index year (patient gender, patient age group at the index date, main prescriber, asthma status at the index date, severity of AR before the index date, and the number of years of SLIT treatment) were not used as matching criteria but were subsequently corrected for in all analyses by multiple regressions (see Appendix S1).
| Study endpoints
The and not during the SLIT treatment period. In contrast, the asthma analyses were performed for the treatment, follow-up, and full analysis periods.
All analyses were performed using SAS software (version 9.3; SAS Institute, Inc., Cary, NC, USA). The threshold for statistical significance was set to P<.05 in all cases.
All patients with a SLIT tablet prescription: 105 069
With an index date in (Table 1 ). In the SLIT tablet group, most exclusions ( Figure 1 ) were due to the index year (excluding 42.6% of all SLIT patients), the need for SLIT to have been administered in at least two successive grass pollen allergy treatment cycles (excluding 53.9%), and the requirement for at least one AR prescription in the year before the index date (excluding 69.4%). In the non-AIT group (Figure 2) , 99.1% of the excluded patients were eliminated due to the lack of an index date.
Although the gender distribution was very similar in the two groups, the age profiles at the index date differed markedly. For example, the proportion of under-18 patients was 48.6% in the SLIT tablet group and 7.5% in the non-AIT group. Accordingly, the proportion of patients with a paediatrician as the main prescriber was higher in the SLIT tablet group than in the non-AIT group (22.1% and 2.1%, respectively). Importantly, the proportion of asthma-free patients at the index date was similar in the SLIT and non-AIT groups (76.9% and 75.4%, respectively; Table 1 ).
| Progression of AR after treatment cessation
In both groups, the mean number of AR prescriptions was lower after treatment cessation than during the preindex period. However, 
| New asthma onset
In the full analysis period, the proportion of initially asthma-free patients with new asthma onset was lower in the SLIT tablet group (n=208, 9.5%) than in the non-AIT group (n=6222, 11.6%). After adjustment for covariates, the odds ratio [95% CI] for new asthma onset evidenced a reduction in the risk of asthma onset in the SLIT tablet group in all three analytical time periods (Table 3 ). The relative risk reduction was around 30% during treatment and around 40%
during follow-up.
| Time to asthma onset
The analysis of the time to first prescription of SABAs or ICSs was unclear when comparing the SLIT tablet and non-AIT groups during the first year of treatment: The Kaplan-Meier curves for the two groups were essentially superimposed until 10 months after the index date ( Figure 3) . Thereafter, the curves diverged, and the SLIT tablet group's curve was consistently above that of the non-AIT group. The difference between the two curves could not be analyzed in a valid way using Cox regression, due to a significant violation of the PH assumption (P=.02 in a supremum test). When the analysis was restricted to the follow-up period (Figure 4 ), the PH assumption 
| Progression of asthma
In patients with asthma during the preindex period (Table 1) , the mean number of asthma prescriptions was slightly higher in the SLIT tablet group (3.38 per year) than in the non-AIT group (3.00 per 
F I G U R E 3
Time to asthma onset, defined as time to the date of first prescriptions of short-acting b-agonists or inhaled corticosteroids for sublingual immunotherapy (SLIT) and non-AIT groups during the full analysis period, in patients without asthma at the index date (note the offset of the y-axis) F I G U R E 4 Time to asthma onset, defined as time to the date of first prescriptions of short-acting b-agonists or inhaled corticosteroids for sublingual immunotherapy (SLIT) and non-AIT groups during the follow-up period, in patients without asthma at the end of treatment period (note the offset of the y-axis)
As preceding, data were adjusted for covariates. Once data adjusted, a linear regression showed that the progression of asthma was consistently and significantly slower in the SLIT tablet group ( 
| DISCUSSION
In the SLIT tablet group, the intensity of AR treatment with symptomatic medications decreased after AIT initiation. This finding is in line with the reduction in medication scores generally observed in DBPC RCTs of grass pollen SLIT tablet. 17 However, the absolute reductions in medication use seen in DBPC RCTs and in dataset analyses cannot be compared directly.
As mentioned in the Introduction, a few clinical studies have investigated the preventive effect of AIT on asthma onset in AR patients. [24] [25] [26] [27] [28] [29] [30] Novembre et al. 27 randomly assigned 113 children with grass pollen-induced AR to either 3 years of SLIT or 3 years of standard pharmacotherapy alone. At the end of the treatment period, the proportion of patients having developed asthma was significantly lower (P=.0412) in the SLIT group (18%) than in the pharmacotherapy-only group (40%). Similarly, Marogna et al. 28 assigned 216 children with AR to either 3 years of SLIT or 3 years of pharmacotherapy alone. Again, the proportion of patients with asthma after 3 years was significantly lower in the SLIT group than in the pharmacotherapy-only group (1.5% vs 29% for persistent asthma; P<.001).
The results of the PAT study showed that a 3-year course of SCIT with standardised allergen (grass pollen and birch) in children was associated with a significantly lower incidence of asthma (relative to symptomatic medication alone) at the end of the treatment period and even 5 and 7 years after treatment cessation. [24] [25] [26] In contrast, the GAP study in children failed to observe a relative reduction in the time to diagnosis of a reversible impairment of lung function. 29 Nevertheless, there was a clinically meaningful treatment effect on asthma symptoms in patients having developed the condition. Similarly, Schmitt et al.'s recent retrospective cohort analysis of a German regional prescriptions database showed that AIT (all types pooled) decreased the incidence of asthma in patients with AR 30 in a population of both children and adults. Our database analysis provides similar outcomes in a population of adults and children.
This therapeutic area has been addressed in various meta-analyses and systematic reviews; such studies provide unique insights into the comparative effectiveness of a therapeutic intervention (eg, AIT) vs a control (eg, placebo or other pharmacological treatments).
One recent meta-analysis found a low level of evidence to support the concept whereby AIT prevents the onset of new allergen sensitisations, and another found that AIT did not result in a statistically significant reduction in the risk of developing a first allergic disease. 37, 38 However, it must be borne in mind that (i) these analyses may not be able to draw valid conclusions when the data show extremely high clinical and methodological heterogeneity and (ii) not all the studies included in these systematic reviews had the same primary outcome.
| Study limitations and strengths
The present study had some limitations. T A B L E 5 Asthma progression (measured as the intensity of asthma medication use) in the SLIT and non-AIT groups over the follow-up period: regression coefficients; 95% confidence intervals (CI) and P-values of the factors included in the linear regression model Secondly, the two-grass pollen SLIT tablet formulations analyzed here differ in their allergen composition and recommended regimen.
Oralairâ contains pollen extract from five species of grass, whereas
Grazaxâ contains timothy pollen extract only. A three-season preand co-seasonal regimen is recommended for Oralairâ, whereas 3 years of continuous treatment is recommended for Grazaxâ.
Future research in this field could compare the two tablets.
Thirdly, the SLIT tablet and non-AIT groups were only matched for the treatment index year and so differed in some important respects (reflecting real life). The proportion of children and adolescents was markedly higher in the SLIT tablet group, as observed in an earlier German observational study; 30 these observations suggest that physicians in Germany are more likely to prescribe SLIT tablets to younger patients. Overall, specialist physicians accounted for a higher proportion of main prescribers in the SLIT tablet group than in the non-AIT group; this is not unexpected, as the prescription of SLIT requires experience in allergology. In Germany, allergology is an additional medical qualification (gained typically by dermatologists, ENT specialists, and pulmonologists), rather than being a separate medical speciality per se. The higher proportion of paediatricians as main prescribers in the SLIT tablet group reflected the age difference. As part of the allergic march, allergic asthma tends to emerge more frequently in childhood and adolescence than in adulthood. 13 Hence, one would expect to see more asthma onset in a younger population. However, patient age was one of the covariates controlled for in our analyses and did not influence asthma onset. Furthermore, any bias due to patient age in the present study would tend to reduce the effect of SLIT and not increase it. Accordingly, the significant differences in favour of SLIT observed here are likely to be genuine, and the true, underlying effect may be greater still.
Lastly, regarding asthma definition, as mentioned in the method section, depot formulations of systemic corticosteroids are used to measure asthma progression. A sensitivity analysis excluding those was performed and did not impact the results.
The present study also had a number of strengths-the most important of which is its use of real-world data. After a medication has been granted marketing authorization, the reimbursement authorities increasingly request evidence of real-world effective- were based only on a few hundred patients.
| CONCLUSION
The present real-life retrospective analysis is the first to have ana- 
| Future research
Using the same dataset, future research could focus on the real-life, long-term impact of each of the two SLIT tablets (Oralairâ and Grazaxâ) on AR and asthma. The number of patients included in the present study should be sufficient for assessing the long-term effect on AR. However, larger samples sizes would be required for reliable assessment of the impact on asthma (ie, new asthma onset in initially asthma-free patients, and the progression of asthma in patients with current asthma). Given that Oralairâ and Grazaxâ have different administration protocols, exposure could be considered as a variable in a specific analysis. It would also be interesting to assess the impact of grass pollen SLIT tablets on conjunctivitis during treatment and after cessation. Lastly, the same methodology could be applied to studies of SLIT with other allergen sources (eg, birch pollen).
